Cytokinetics (CYTK) Posts Narrower than Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
MLV & Co. Upgrades Cytokinetics (CYTK) to Buy
November 4, 2014 6:49 AM ESTMLV & Co. upgraded Cytokinetics (NASDAQ: CYTK) from Hold to Buy with a price target of $9.00.
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $3.70 yesterday.
... More